TriSalus Life Sciences (TLSI) Earnings Date & Reports

Key Takeaways

• TriSalus Life Sciences (TLSI) reported third quarter 2026 revenue of $12.9 million, up 11.3% year over year and about 13% sequentially, driven by TriNav adoption.
• Revenue and earnings per share (EPS) both missed consensus, with a net loss of $0.15 per share against expectations for a smaller loss.
• Gross margin improved to 86.2% from 83.5% a year earlier, while the operating loss narrowed to $7.7 million.
• Full-year 2026 revenue guidance was cut to $46 million–$48 million, down from the prior $54 million–$57 million range.
• The company received U.S. Food and Drug Administration (FDA) clearance for TriNav Advance, expanding its delivery technology to smaller vessels.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Looking for data-driven trade ideas? Explore Trending AI Robots to see automated strategies in action.

Earnings Context and Why It Matters

TriSalus Life Sciences is an oncology-focused medical technology company whose flagship TriNav Infusion System uses Pressure-Enabled Drug Delivery (PEDD) to deliver therapeutics directly into solid tumors. This quarterly earnings report matters because it tests whether the company's aggressive commercial expansion, which more than doubled its sales force earlier in 2026, is translating into revenue. After a weak first quarter and a modest second quarter, investors were watching closely for a reacceleration in TriNav volumes. The report also carries broader implications: new FDA clearance for TriNav Advance and favorable 2027 Medicare reimbursement changes could reshape the company's growth runway, even as repeated guidance cuts have dented confidence in the near-term trajectory.

Reported Results

TriSalus reported third quarter 2026 revenue of $12.9 million, up 11.3% from $11.6 million in the prior-year period and roughly 13% sequentially from $11.4 million in the second quarter. The result fell short of the approximately $14 million in consensus revenue, and the company's net loss of $0.15 per share was slightly wider than the roughly $0.14 loss analysts had expected.

Gross margin rose to 86.2% from 83.5% a year ago, reflecting lower production costs per TriNav unit. Operating loss narrowed to $7.7 million from $9.0 million, helped by lower research and development and administrative expenses, though sales and marketing spending increased to support the expanded field force. Net loss attributable to common stockholders was $8.9 million, down sharply from $41.3 million a year earlier, a comparison distorted by roughly $30.5 million in prior-year charges tied to preferred stock conversion. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss improved to $4.7 million from $5.4 million.

The company ended the quarter with $41.1 million in cash and cash equivalents.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, the tool helps streamline the research process for both retail and professional investors. Explore the AI Screener to apply these filters and uncover signals relevant to your watchlist.

Market Reaction and Investor Sentiment

Sentiment heading into the print was cautious after two consecutive quarters of softer-than-expected results, and the third quarter extended that streak. The revenue and EPS misses, combined with the third straight cut to full-year guidance, weighed on the stock in early trading. Investors appeared to focus less on the improving gross margin and narrowed operating loss, and more on the slower-than-anticipated ramp of newly hired sales representatives. The sequential revenue rebound and FDA clearance for TriNav Advance offered a partial offset, but the market's attention remained on whether management can convert an expanded commercial footprint into sustained, forecast-beating growth in 2027.

Forward Outlook and Key Factors to Monitor

The most important near-term development is the revised full-year 2026 revenue guidance of $46 million to $48 million, implying only about 2% to 6% growth compared with 2025. That marks a meaningful step down from the prior $54 million to $57 million range, which itself was lowered from an original $60 million to $62 million. Management attributed the shortfall primarily to slower sales representative productivity, particularly in newer expansion territories, and a faster-than-expected shift toward super-selective Y90 procedures in small distal vessels.

Investors should watch several catalysts heading into 2027. The limited market release of TriNav Advance, cleared by the FDA in September, is not yet contributing to fourth quarter guidance, so its broader launch will be a key growth lever. On the reimbursement side, changes from the Centers for Medicare & Medicaid Services (CMS) take effect January 1, 2027, including a higher national payment rate for certain hospital procedures and a new office-based payment arrangement that could open an additional channel.

Finally, the company expects initial data from the PROTECT registry on thyroid artery embolization in the first quarter of 2027, which could broaden the addressable market. With a cash balance of $41.1 million and continued investments in the commercial organization, the path to sustained double-digit growth and reduced cash burn will be central to investor sentiment in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations